CLDX Stock Analysis: Celldex Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.012m USD | 12M Return: 80.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 35.1M
Qual. Beats: 0
Rev. Trend: -54.0%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is a clinical-stage biopharmaceutical company headquartered in Hampton, New Jersey, that develops therapeutic antibodies for patients with severe inflammatory, allergic, and autoimmune diseases. The company focuses on mast cell mediated diseases where existing treatments are inadequate, building its pipeline around monoclonal and bispecific antibody candidates. Its lead program, Barzolvolimab (CDX-0159), is a monoclonal antibody targeting the KIT receptor and is being evaluated across multiple indications including chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis. A second candidate, CDX-622, is a bispecific antibody designed to neutralize thymic stromal lymphopoietin and deplete mast cells through stem cell factor starvation.
As a biotechnology company in the GICS Health Care sector, Celldex operates a research-and-development-driven business model typical of clinical-stage biopharma firms, where revenue is generally limited to collaboration or grant arrangements until products reach commercialization. Monoclonal antibodies represent one of the largest and most established classes of biologic therapeutics, with regulatory approval and commercial success heavily dependent on clinical trial outcomes and FDA review processes.
- Barzolvolimab Phase 3 chronic urticaria data readouts approach
- FDA breakthrough designation expands addressable market for lead antibody
- Cash burn and dilution risk as clinical pipeline expands
| Net Income: -283.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.44 > 0.02 and ΔFCF/TA -20.91 > 1.0 |
| NWC/Revenue: 49.7k% < 20% (prev 8.75k%; Δ 41.0k% < -1%) |
| CFO/TA -0.43 > 3% & CFO -222.2m > Net Income -283.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (66.6m) vs 12m ago 0.28% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.13% > 50% (prev 1.02%; Δ -0.89% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.80 (Total Current Assets 459.2m - Total Current Liabilities 51.5m) / Total Assets 511.3m |
| B: -3.70 (Retained Earnings -1.89b / Total Assets 511.3m) |
| C: -0.45 (EBIT TTM -283.7m / Avg Total Assets 625.4m) |
| D: 8.29 (Book Value of Equity 456.2m / Total Liabilities 55.0m) |
| Altman-Z'' = -1.18 = CCC |
| DSRI: 1.99 (Receivables 230k/1.06m, Revenue 820k/7.56m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.64 (AQ_t 0.08 / AQ_t-1 0.05) |
| SGI: 0.11 (Revenue 820k / 7.56m) |
| TATA: -0.12 (NI -283.7m - CFO -222.2m) / TA 511.3m) |
| Beneish M = -2.48 (Cap -4..+1) = BBB |
As of July 07, 2026, the stock is trading at USD 37.95 with a total of 439,196 shares traded. Over the past week, the price has changed by +7.63%, over one month by +32.88%, over three months by +20.98% and over the past year by +80.89%.
Current recommended Stop Loss: 36.00 (which is 5.1% or 1.3 ATR below the current price).
Celldex Therapeutics has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy CLDX.
- StrongBuy: 12
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 57.5 | 51.6% |
P/S = 3481.781
P/B = 6.6014
Revenue TTM = 820k USD
EBIT TTM = -283.7m USD
EBITDA TTM = -280.3m USD
Long Term Debt = 443k USD (estimated: total debt 1.91m - short term 1.47m)
Short Term Debt = 1.47m USD (from shortTermDebt, last quarter)
Debt = 1.91m USD (from shortLongTermDebtTotal, last quarter) (leases 1.91m already included)
Net Debt = -449.6m USD (calculated: Debt 1.91m - CCE 451.5m)
Enterprise Value = 2.56b USD (3.01b + Debt 1.91m - CCE 451.5m)
Interest Coverage Ratio = unknown (Ebit TTM -283.7m / Interest Expense TTM 0.0)
EV/FCF = -11.34x (Enterprise Value 2.56b / FCF TTM -226.0m)
FCF Yield = -8.82% (FCF TTM -226.0m / Enterprise Value 2.56b)
FCF Margin = -27.6k% (FCF TTM -226.0m / Revenue TTM 820k)
Net Margin = -34.6k% (Net Income TTM -283.7m / Revenue TTM 820k)
Gross Margin = unknown ((Revenue TTM 820k - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 5.01 (Enterprise Value 2.56b / Total Assets 511.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.91m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -224.1m (EBIT -283.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.92 (Total Current Assets 459.2m / Total Current Liabilities 51.5m)
Debt / Equity = 0.00 (Debt 1.91m / totalStockholderEquity, last quarter 456.2m)
Debt / EBITDA = 1.60 (negative EBITDA) (Net Debt -449.6m / EBITDA -280.3m)
Debt / FCF = 1.99 (negative FCF - burning cash) (Net Debt -449.6m / FCF TTM -226.0m)
Total Stockholder Equity = 559.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.36% (Net Income -283.7m / Total Assets 511.3m)
RoE = -50.72% (Net Income TTM -283.7m / Total Stockholder Equity 559.3m)
RoCE = -50.68% (EBIT -283.7m / Capital Employed (Equity 559.3m + L.T.Debt 443k))
RoIC = -48.59% (negative operating profit) (NOPAT -224.1m / Invested Capital 461.2m)
WACC = 10.00% (E(3.01b)/V(3.01b) * Re(10.01%) + D(1.91m)/V(3.01b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 70.76 | Cagr: 15.98%
[DCF] Fair Price = unknown (Cash Flow -226.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.47 | # QB: 0
Revenue Correlation: -54.03 | Revenue CAGR: -36.49% | SUE: -0.64 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.07 | Chg30d=-0.35% | Revisions=+57% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-1.08 | Chg30d=-0.12% | Revisions=+38% | Analysts=10
EPS current Year (2026-12-31): EPS=-4.39 | Chg30d=-0.06% | Revisions=+67% | GrowthEPS=-12.6% | GrowthRev=+70.5%
EPS next Year (2027-12-31): EPS=-4.50 | Chg30d=+1.06% | Revisions=+50% | GrowthEPS=-2.4% | GrowthRev=+354.0%
[Analyst] Revisions Ratio: +72% (up=20, down=2)